Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis

CONCLUSIONS: Irbesartan could be used in combination with chemotherapy to improve the therapeutic efficacy in PDAC patients with high levels of c-Jun expression. Irbesartan effectively inhibited chemotherapy resistance by suppressing the Hippo/YAP1/c-Jun/stemness/iron metabolism axis. Based on our findings, we are designing an investigator-initiated phase II clinical trial on the efficacy and safety of irbesartan plus a standard gemcitabine/nab-paclitaxel regimen in the treatment of patients with advanced III/IV staged PDAC and are hopeful that we will observe patient benefits.PMID:37143164 | PMC:PMC10157938 | DOI:10.1186/s13046-023-02671-8

Source: Clinical Breast Cancer - May 4, 2023 Category: Cancer & Oncology Authors: Tianxing Zhou Yongjie Xie Xupeng Hou Weiwei Bai Xueyang Li Ziyun Liu Quan Man Jingyan Sun Danqi Fu Jingrui Yan Zhaoyu Zhang Yifei Wang Hongwei Wang Wenna Jiang Song Gao Tiansuo Zhao Antao Chang Xiuchao Wang Hongxia Sun Xiufeng Zhang Shengyu Yang Chongbiao Source Type: research